Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

181. Acupuncture for vasomotor menopausal symptoms: a systematic review

Acupuncture for vasomotor menopausal symptoms: a systematic review Acupuncture for vasomotor menopausal symptoms: a systematic review Acupuncture for vasomotor menopausal symptoms: a systematic review Cho SH, Whang WW CRD summary The review concluded that there was no consistent evidence that acupuncture was effective for treating menopausal vasomotor symptoms compared to sham acupuncture or hormone therapy; further research was warranted. The review was well conducted in most respects (...) and these cautious conclusions appear reliable. Authors' objectives To determine the effectiveness and tolerability of acupuncture for reducing menopausal vasomotor symptoms. Searching Nineteen electronic databases were searched to July 2008 (these included The Cochrane Library, MEDLINE, EMBASE, AMED, CINAHL, PsycINFO, Current Controlled Trials, NCCAM, www.library.nhs.uk/cam/, Japan Science and Technology Information Aggregator Electronic and several Korean and Chinese databases). Relevant journals

2009 DARE.

182. A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture

A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture A study to establish (...) the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping bisphosphonate treatment after 5 years in post-menopausal women with osteoporosis who have already had a fracture Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL Citation Stevenson MD, Oakley JE, Lloyd Jones M, Brennan A, Compston JE, McCloskey EV, Selby PL. A study to establish the feasibility of a trial that would investigate the clinical and cost-effectiveness of stopping

2009 Health Technology Assessment (HTA) Database.

183. Acupuncture for treating menopausal hot flushes: a systematic review

Acupuncture for treating menopausal hot flushes: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

184. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

185. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany

Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

186. Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review

Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

187. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis

Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

188. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis (PubMed)

Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis Treatment decisions about menopause are predicated on a transient duration of vasomotor symptoms. However, evidence supporting a specific duration is weak.To estimate the natural progression of vasomotor symptoms during the menopause transition by systematically compiling available evidence using meta-analytic techniques.We searched MEDLINE, hand searched secondary references in relevant studies, book chapters (...) , and review papers, and contacted investigators about relevant published research.English language, population-based studies reporting vasomotor symptom prevalence among women in menopausal transition in time intervals based on years to or from final menstrual period were included. Two reviewers independently assessed eligibility and quality of studies and extracted data for vasomotor symptom prevalence.The analyses included 10 studies (2 longitudinal, 8 cross sectional) with 35,445 participants

Full Text available with Trip Pro

2008 EvidenceUpdates

189. Medical care for menopausal and older women with HIV infection.

Medical care for menopausal and older women with HIV infection. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding for the National Guideline

2008 New York State Department of Health

190. Herbal supplements did not relieve vasomotor symptoms of menopause in women

Herbal supplements did not relieve vasomotor symptoms of menopause in women Herbal supplements did not relieve vasomotor symptoms of menopause in women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Herbal supplements did not relieve vasomotor symptoms of menopause in women Article Text Therapeutics Herbal supplements did not relieve vasomotor symptoms of menopause in women Statistics from Altmetric.com Request Permissions If you

2008 Evidence-Based Medicine (Requires free registration)

191. Menopause. (PubMed)

Menopause. Menopause is the time of life when menstrual cycles cease, and is caused by reduced secretion of the ovarian hormones oestrogen and progesterone. Although menopause is a normal event for women, individual experiences vary, and some women seek medical advice for the management of symptoms. Many symptoms have been attributed to menopause, but only vasomotor dysfunction and vaginal dryness are consistently associated with this time of life in epidemiological studies. Other common (...) symptoms such as mood changes, sleep disturbances, urinary incontinence, cognitive changes, somatic complaints, sexual dysfunction, and reduced quality of life may be secondary to other symptoms, or related to other causes. Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with other agents; adverse effects of these treatments must also be considered. Many questions about menopausal transition and its

2008 Lancet

192. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. (PubMed)

Increased risk of parkinsonism in women who underwent oophorectomy before menopause. There is increasing laboratory evidence for a neuroprotective effect of estrogen on the nigrostriatal pathway; however, the epidemiologic evidence remains limited and conflicting. We studied the association of oophorectomy performed before the onset of menopause with the risk of subsequent parkinsonism.We included all women who underwent either unilateral or bilateral oophorectomy before the onset of menopause (...) -linkage system, and death certificates.Women who underwent either unilateral or bilateral oophorectomy before the onset of menopause had an increased risk of parkinsonism compared with referent women (HR 1.68; 95% CI 1.06 to 2.67; p = 0.03), and the risk increased with younger age at oophorectomy (test for linear trend; p = 0.01). The findings were similar regardless of the indication for the oophorectomy, and for unilateral or bilateral oophorectomy considered separately. The findings were also

2008 EvidenceUpdates

193. Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms

Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: sparse good quality evidence supports the use of alternative therapies for menopausal symptoms Article Text Treatment Review: sparse good quality evidence supports the use

2008 Evidence-Based Nursing

194. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials

Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials Ma D F, Qin, L Q, Wang P Y, Katoh R CRD summary This review (...) and serum bone-specific alkaline phosphatase (BAP) as a marker of bone formation. Included studies used either soy protein containing mainly isoflavones or isoflavone tablets. Isoflavone intake ranged from 37.3 to 118 mg/day and treatment duration from four to 48 weeks. Studies enrolled either Caucasian or Asian women who were not undergoing other osteoporosis therapy, and the majority enrolled post-menopausal women, with mean ages ranging from 51 to 62.4 years. All studies restricted common soy foods

2008 DARE.

195. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials

Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials Ma D F, Qin L Q, Wang P Y, Katoh R CRD summary The authors concluded that isoflavones significantly (...) reduced spine bone loss in menopausal women; effects were greater when more than 90mg/day of isoflavones was consumed and isoflavone was taken for six months. The evidence appears to support the authors’ conclusions, but the non significant results at 12 months were unexplained and may weaken the strength of evidence supporting the reported benefits of isoflavones. Authors' objectives To evaluate the effect of isoflavones on spinal bone mass in women. Searching MEDLINE (from 1966), EMBASE (from 1985

2008 DARE.

196. Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women. Applied Health Economics and Health Policy 2008; 6(2-3): 113-135 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Absorptiometry, Photon /economics; Aged; Aged, 80 and over; Alendronate /economics /therapeutic use; Bone Density; Bone Density Conservation Agents /economics /therapeutic use; Bone and Bones /ultrasonography; Cost-Benefit Analysis; Female; Fractures, Bone /economics

2008 NHS Economic Evaluation Database.

197. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy

Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

198. Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause

Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined HRT increased CV events more than placebo but did not differ from oestrogen HRT after menopause Article Text Therapeutics Combined HRT increased CV events more than

2008 Evidence-Based Medicine (Requires free registration)

199. Phytoestrogens for vasomotor menopausal symptoms. (PubMed)

Phytoestrogens for vasomotor menopausal symptoms. Vasomotor symptoms, such as hot flushes and night sweats, are very common during the menopausal transition. Hormone replacement therapy has traditionally been used as a very effective treatment but concerns over increased risks of some chronic diseases have markedly increased the interest of women in alternatives. Some of the most popular of these are treatments based on foods or supplements enriched with phytoestrogens, plant-derived chemicals (...) from 1% to 59% with placebo. There was no indication that the discrepant results were due to the amount of isoflavone in the active treatment arm, the severity of vasomotor symptoms or trial quality factors. There was also no evidence that the treatments caused oestrogenic stimulation of the endometrium (an adverse effect) when used for up to two years.There is no evidence of effectiveness in the alleviation of menopausal symptoms with the use of phytoestrogen treatments.

2007 Cochrane

200. Exercise for vasomotor menopausal symptoms. (PubMed)

Exercise for vasomotor menopausal symptoms. Evidence suggests that a high proportion of perimenopausal and early postmenopausal women will experience some menopause symptoms, hot flushes being the most common. The effects caused by falling levels of estrogen may be alleviated by hormone replacement therapy (HRT) but there has been a marked global decline in the prescription and use of HRT due to concerns about the risks and benefits of HRT; consequently many women are now seeking alternatives (...) . As large numbers of women are choosing not to take HRT, it is increasingly important to identify evidence based lifestyle modifications, which can have a positive effect on menopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotor menopausal symptoms (hot flushes and night sweats) in perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials

2007 Cochrane